{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-268944","form_type":"8-K","ticker":"KYMR","cik":"0001815442","company_name":"Kymera Therapeutics, Inc.","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.620702+00:00","generated_at":"2026-06-09T00:51:13.528611+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Kymera reports Phase 1 data for STAT3 degrader KT-333: one PR in CTCL, no DLTs","bullets":["21 patients enrolled through dose level 5; 12 evaluable for disease assessment.","One partial response in cutaneous T-cell lymphoma (CTCL) at DL2; stable disease in 3 solid tumor patients (DL3/4).","No dose-limiting toxicities or serious adverse events; most AEs Grade 1/2 (constipation, fatigue, nausea, anemia).","Dose-dependent, sustained STAT3 degradation in PBMCs at DL3+ at levels linked to preclinical anti-tumor activity.","Updated data to be presented at ASH 2023 on December 10."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-268944","json":"https://secwatch.observer/filing/0001193125-23-268944.json","markdown":"https://secwatch.observer/filing/0001193125-23-268944.md","text":"https://secwatch.observer/filing/0001193125-23-268944.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815442/000119312523268944/0001193125-23-268944-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815442/000119312523268944/d590090d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T00:51:13.528611+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}